Drug Trial Radar · NCT06916078
A Study of Lepodisiran (LY3819469) in Participants With Normal, Mild, Moderate, or Severe Liver Function
Last checked: Nov 20, 2026Latest source record: Aug 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
30
Actual
Start
Apr 23, 2025
Primary completion
Jul 13, 2026
Study completion Jul 13, 2026
Sponsor
- Lead sponsor
- Eli Lilly and CompanyEli Lilly (LLY)
- Sponsor type
- Industry
- First posted
- Apr 8, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Basic science
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The main purpose of this study is to evaluate how much lepodisiran gets into the blood stream and how long it takes the body to get rid of it when given as a subcutaneous (SC) injection under the skin to participants with mild, moderate, or severe liver function impairment compared to participants with normal liver function. The study will also evaluate how well lepodisiran is tolerated and what side effects may occur in these participants. The study will last up to approximately 9 weeks, excluding screening.
Conditions
- Liver Dysfunction
- Healthy
Interventions
LepodisiranDrug
Lepodisiran administered SC
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of LepodisiranTime frame: Baseline Up to 9 weeks
- PK: Maximum Concentration (Cmax) of LepodisiranTime frame: Baseline Up to 9 weeks
Locations
4 sites in 2 countries. Site status is shown where the registry gives one.
Clinical Pharmacology of Miami
Miami, Florida
Orlando Clinical Research Center
Orlando, Florida
American Research Corporation at Texas Liver Institute
San Antonio, Texas
CRU Early Phase Unit
Kistarcsa, Hungary
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.